Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions:   Pancreatic Cancer;   Breast Cancer;   Gastric Cancer;   Non Small Cell Lung Cancer;   Cervical Cancer;   Endocervical Cancer;   Squamous Cell Carcinoma of Head and Neck;   Bladder Urothelial Cancer;   Colorectal Cancer;   Esophageal Cancer;   Ovarian Cancer;   Rena l Cell Carcinoma;   Prostate Cancer;   Melanoma;   Mesothelioma;   Cholangiocarcinoma Interventions:   Drug: NGM438;   Drug: NGM438 plus pembrolizumab Sponsor:   NGM Biopharmaceuticals, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2022 Category: Research Source Type: clinical trials

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Conditions:   Malignant Pleural Mesothelioma;   Unresectable Malignant Neoplasm Intervention:   Other: Data collection Sponsors:   Groupe Francais De Pneumo-Cancerologie;   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2022 Category: Research Source Type: clinical trials